ORIGINAL ARTICLE. of consequences 1-15 undoubtedly contribute to the difficulty in specifying
|
|
- Paula Campbell
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Use of Pattern Analysis to Predict Differential Relapse of Remitted Patients With Major Depression During 1 Year of Treatment With Fluoxetine or Placebo Jonathan W. Stewart, MD; Frederic M. Quitkin, MD; Patrick J. McGrath, MD; Jay Amsterdam, MD; Maurizio Fava, MD; Jan Fawcett, MD; Frederick Reimherr, MD; Jerrold Rosenbaum, MD; Charles Beasley, MD; Paul Roback, MS Background: Delayed and persistent ( true drug ) improvement characterizes the response to antidepressant medication. Early or nonpersistent ( placebo ) benefit is typical of a placebo response. The prediction was that patients with a true drug response would sustain their benefit best if they continued to receive the drug and that patients with a placebo response would have an equivalent prognosis whether they continued to receive the drug or were switched to placebo. Methods: Patients with major depression who met the study s response criteria (a modified Hamilton Depression Rating Scale score 7 and failure to meet major depression criteria after each of the last 3 weeks following 12 to 14 weeks of treatment with fluoxetine hydrochloride, 20 mg/d) were enrolled in a 50-week randomized placebo substitution trial during which the return of depressive symptoms defined relapse. The timing and persistency of response during initial treatment defined true drug or placebo response patterns. Results: Patients with a true drug response pattern relapsed significantly more frequently if they were switched to placebo than if they continued to receive fluoxetine (P.001 for weeks 12-26, P.005 for weeks 26-50, and P.41 for weeks 50-62). Patients with a placebo response pattern had an equivalent outcome whether maintained on fluoxetine therapy or placebo (P.20 for weeks 12-26, test invalid for weeks 26-50, and P.67 for weeks 50-62). Patients with a placebo response pattern relapsed more often when they continued to receive fluoxetine than patients with a true drug response pattern (P.01 for weeks 12-26, P.10 for weeks 26-50, and P.36 for weeks 50-62). Conclusions: These findings confirm that pattern analysis validly differentiates true drug from nonspecific initial responses and extend its use to the continuation and maintenance phases of treatment for depression. Investigations into the mechanisms of antidepressant activity might best be limited to those that can account for delayed efficacy. Fluoxetine s efficacy during the continuation and maintenance phases of treatment may be limited to patients with a true drug pattern of initial response. Arch Gen Psychiatry. 1998;55: From the Department of Psychiatry, New York State Psychiatric Institute, New York (Drs Stewart, Quitkin, and McGrath); Department of Psychiatry, University of Pennsylvania, Philadelphia (Dr Amsterdam); Department of Psychiatry, Massachusetts General Hospital, Boston (Drs Fava and Rosenbaum); Department of Psychiatry, Rush-Presbyterian St Luke s Medical Center, Chicago, Ill (Dr Fawcett); Department of Psychiatry, University of Utah, Salt Lake City (Dr Reimherr); Eli Lilly Corporation, Indianapolis, Ind (Dr Beasley); and Department of Statistics, Colorado State University, Fort Collins (Mr Roback). DIVERSE timing1,2 and a plethora of consequences 1-15 undoubtedly contribute to the difficulty in specifying the critical mechanisms of antidepressant effects. 16 The success of investigations into these mechanisms would be improved if studies were restricted to biological processes having timing similar to that of efficacy. Identifying how antidepressants work might offer clues about the pathophysiological features of depressive illness and allow predictability of treatment outcome. Treatment response is inherently heterogeneous, rendering problematic its use to validate proposed mechanisms. Typically, two thirds of patients with depression improve while taking active medication and one third remit while taking placebo. 17 Subtracting the placebo response, about one third benefit from the specific effects of antidepressant medications and one third improve because of nonspecific effects. That is, of those who improve while taking medication, about half do so for reasons other than direct pharmacological effects. Studies usually compare all patients who improve while taking a drug (ie, a mixed group of those requiring medication plus nonspecific responders) with a control group or with nonresponders. Methods that differentiated a true drug response from a nonspecific response would aid research into the biological features of depressive disorders and decisions about whether to continue the administration of an apparently effective medication. Pattern analysis 18 makes this distinction. Several studies validate a 334
2 PATIENTS AND METHODS To test the hypotheses that the timing and persistence of a short-term benefit will predict long-term outcome, we used data from a multisite study designed to determine the optimal duration of fluoxetine treatment. Five sites enrolled patients with major depression into an open, 12-week trial of fluoxetine; responders then received continued therapy for up to 1 year, during which three quarters were switched to placebo at 1 of 3 points (Figure 1). Each site followed an identical protocol. PATIENT POPULATION All study subjects were outpatients aged between 18 and 65 years, were physically healthy, met the DSM-III-R 22 criteria for major depression, and had a modified 17-item Hamilton Depression Rating Scale 23 (mhamd) score of 16 or more. The mhamd substituted hypersomnia and hyperphagia for insomnia, anorexia, and weight loss items in patients with reverse vegetative symptoms. Patients were excluded for unstable medical illnesses, pregnancy or lactation, serious suicidal impulses, history of psychosis, organic mental disorder, mania or antisocial personality disorder, substance abuse disorder in the past year, hypothyroidism, previous fluoxetine treatment for longer than 1 week in the current episode or longer than 3 months in a previous episode, or lack of a response to 8 weeks of treatment with fluoxetine hydrochloride, 20 mg/d. CONSENT PROCEDURE Signed, informed consent was obtained from each patient and approved by each site s institutional review board. Patients were told that the Eli Lilly Corp, Indianapolis, Ind, sponsored the study to determine the long-term efficacy of fluoxetine and that if their condition initially improved, placebo might be substituted for fluoxetine at some time during the ensuing 11 months. If depressive symptoms returned during the double-blind phase, they were instructed to call immediately for an evaluation. They were told that treatment would continue after the end of the study, including the reinstitution of fluoxetine therapy if appropriate. INITIAL 12 WEEKS OF TREATMENT Patients whose symptoms persisted during a drug-free observation week were treated openly with fluoxetine hydrochloride, 20 mg/d, for 12 weeks. The mhamd and Clinical Global Impression 24 Global Severity scores were obtained at each visit (weekly for weeks 1-4 and and biweekly for weeks 6-10). Remission was defined as an mhamd score of 7 or less and failure to meet the DSM-III-R criteria for major depression after each of the last 3 weeks of the 12-week trial. For most patients, this was weeks 10 through 12. If the mhamd score equaled 8 to 10 at week 10 or 11, they continued to receive fluoxetine 1 or 2 extra weeks, and the ratings for weeks 11 through 13 or 12 through 14 determined whether the remission criteria were met. CREATION OF PATTERNS Prior studies derived response patterns from the Clinical Global Impression Global Improvement score, which was not obtained in this trial. We substituted the Clinical Global Impression Global Severity score. A score of 1 ( no psychopathology ) or 2 ( minimal psychopathology ) identified an improved week; other scores (ie, 3 [ mild psychopathology ] to 7 [ extreme psychopathology ]) defined unimproved weeks. Improvement was early if week 1 or 2 was rated improved. Late improvement occurred if the first improved week was after week 2. Persistent response occurred if an improved week was never followed by an unimproved week. The pattern was nonpersistent if an unimproved week followed an improved week. RANDOMIZATION Responders were randomly assigned within site by a computergenerated code to 1 of 4 groups: 1, immediate placebo substitution; 2, continuation of fluoxetine therapy for 14 weeks followed by placebo substitution; 3, continuation of fluoxetine therapy for 38 weeks followed by placebo substitution; or 4, continuation of fluoxetine therapy for 50 weeks. Opaque envelopes contained each patient s treatment code, to be opened only in an emergency. Otherwise, the treatment code was known only to Eli Lilly Corp staff not involved with clinical decisions. Placebo substitution was immediate, without tapering. TREATMENT DURING CONTINUATION AND MAINTENANCE PHASES After randomization, treatment was double-blind and patients were seen weekly for 2 weeks, then biweekly for 16 weeks, and then monthly. Extra visits were scheduled if depressive symptoms returned. Relapse was defined as either (1) an mhamd score of 14 or more for 3 consecutive weeks or (2) having met the DSM-III-R criteria for major depression for 2 consecutive weeks. HYPOTHESES Three hypotheses were studied: 1. Patients with a true drug response pattern will relapse more often while taking placebo than while taking continued medication. 2. The relapse rates of patients with a placebo pattern of response will not depend on treatment. 3. While continuing to receive fluoxetine, patients with placebo response patterns will relapse more frequently than patients with true drug response patterns. STATISTICAL ANALYSES First, randomization groups were compared for distribution of pattern type. Next, each pair of groups to be compared in the analyses was tested for site, demographic, and illness differences. Sites were compared for different rates of relapse and pattern type. Continuous variables were tested by the t test, and categorical variables were tested by the 2 test with Yates correction in 2 2 contingency tables. Because 117 comparisons were performed (13 variables times 3 hypotheses each tested at 3 points), we considered P.001 to identify nonrandom differences. The primary analysis for each hypothesis tested whether relapse during weeks 12 to 26 differed between Continued on next page 335
3 comparison groups. The log-rank test assessed Kaplan- Meier survival curves for differences in time to relapse between groups. Secondary analyses included similar Kaplan- Meier analyses for weeks 26 to 50 and 50 to 62. Hypothesis 2, predicting no difference between treatments in patients with a placebo response pattern, asserts the null hypothesis, which cannot be directly demonstrated. Therefore, in addition to conventional significance testing, we also provide a power analysis to suggest the smallest relapse difference this sample size could be expected to detect. Only if there is the power to detect a difference too small to be clinically meaningful would it be reasonable to accept the hypothesis of equivalence. All analyses were performed for the period immediately following each placebo substitution point (ie, 12, 26, and 50 weeks) until the next substitution point or end of the study. Analyses testing hypothesis 1 compared patients with the true drug pattern randomized to group 1 (placebo) (n=63) with those randomized to groups 2 through 4 (continued fluoxetine therapy) (n=191) for weeks 12 to 26 (primary analysis); those in group 2 (placebo) (n=41) with those in groups 3 and 4 (continued fluoxetine therapy) (n=69) for weeks 26 to 50; and those in group 3 (placebo) (n=26) with those in group 4 (continued fluoxetine therapy) (n=19) for weeks 50 to 62 (secondary analyses). For hypothesis 2, analyses compared patients with the placebo pattern randomized to group 1 (placebo) (n=32) with those randomized to groups 2 through 4 (continued fluoxetine therapy) (n=106) for weeks 12 to 26 (primary analysis); those in group 2 (placebo) (n=11) with those in group 3 or 4 (continued fluoxetine therapy) (n=37) for weeks 26 to 50; and those in group 3 (placebo) (n=8) with those in group 4 (continued fluoxetine therapy) (n=9) for weeks 50 to 62 (secondary analyses). Analyses for hypothesis 3 compared fluoxetine-treated patients with a true drug pattern with fluoxetine-treated patients with a placebo pattern. This was groups 2 through 4 (n=191 and n=106) for weeks 12 to 26 (primary analysis) and groups 3 and 4 (n=69 and n=37) for weeks 26 to 50 and group 4 (n=19 and n=9) for weeks 50 to 62 (secondary analyses) (the first n values are for patients with a true drug pattern of initial response, and the second n values are for patients with a placebo pattern of initial response). Patients who did not complete the study period were censored after they left the study. All tests of hypotheses were 2 tailed and used an =.05. delayed and persistent short-term response as characterizing patients who improve while receiving antidepressant medications, whereas early or nonpersistent responses are typical of patients responding to placebo. A demonstration that short-term response patterns alter subsequent prognosis would further validate pattern analysis. This article examines the predictive validity of pattern analysis in a 14-month study of fluoxetine. Fluoxetine Hydrochloride, 20 mg/d Fluoxetine Hydrochloride, 20 mg/d Placebo Fluoxetine Hydrochloride, 20 mg/d RESULTS Placebo Fluoxetine Hydrochloride, 20 mg/d Placebo No. of Weeks Receiving Fluoxetine Figure 1. Study design and randomization groups. Group 1, responders after the 12-week trial who were immediately switched to placebo; group 2, responders after the 12-week trial who continued to receive fluoxetine hydrochloride therapy for an additional 14 weeks and then were switched to placebo; group 3, responders after the 12-week trial who continued to receive fluoxetine therapy for an additional 38 weeks and then were switched to placebo; and group 4, responders after the 12-week trial who continued to receive fluoxetine therapy for an additional 50 weeks. The use of short-term response patterns in predicting outcome is examined; the relationship of outcome to fluoxetine blood levels has been reported, 25 while other study aspects will be reported elsewhere, including short-term treatment outcome, general outcome during continuation and maintenance therapy and side effects. Of 839 patients who began to receive medication, 428 met the response criteria. Of these 428 patients, 33 refused treatment or were otherwise determined to be inappropriate candidates for treatment (eg, they had an intercurrent illness or they had moved) and 3 were missing a week 2 rating. Thus, patterns were available for 392 randomized patients who constitute the sample of this report. Table 1 provides the characteristics of these patients. ADEQUACY OF RANDOMIZATION The distribution of patterns among the 4 randomization groups did not differ (Table 2). The 9 pairs of comparison groups did not differ in the distribution of response type or demographic or illness variables (Table 3). The response patterns differed by site as follows: Site True Drug Pattern Placebo Pattern 1 78 (66) 22 (19) 2 60 (35) 40 (23) 3 63 (71) 37 (42) 4 54 (32) 46 (27) 5 65 (50) 35 (27) For this analysis, 2 =9.73, df=4, and P.05. The data are given as the percentage (number) of patients. Relapse rates also differed among sites (Table 4). The effect of site on outcome was, therefore, assessed separately for each period, assuming a proportional hazard for time to relapse. The hazard for relapse was modeled as a function of pattern, treatment, and site, including all 2- and 3-factor interactions. The Cox proportional hazards analysis did not show a significant site-by-pattern-by-treatment interaction for any period: Group 336
4 for the 12-week analysis, Wald test score=5.02, df=1, and P.29; for the 26-week analysis, Wald test score=0.04, df=1, and P.95; and for the 50-week analysis, Wald test score=0, df=1, and ). We also tested whether patients with placebo patterns had different outcomes depending on whether they had an early initial response or a late and nonpersistent initial response. The Kaplan-Meier survival analysis was not significant for any of the periods (log-rank test score=0.09, df=1, P.77 for weeks 19-26; log-rank test score=0.14, df=1, P.71 for weeks 26-50; and log-rank test score=1.21, df=1, P.28 for weeks 50-62). Because sex, site, or placebo pattern subtype were not significant in the analyses described, subsequent analyses did not adjust for these factors. Finally, we investigated whether patients dropped out of the study equally among comparison groups. Patients with a placebo response pattern who were receiving placebo during weeks 26 to 50 dropped out significantly more often than patients with the placebo response pattern who continued to receive fluoxetine, invalidating an assumption of the Kaplan-Meier analysis. The other 8 comparison groups did not differ in their likelihood of dropping out during the risk period (Table 5). TESTS OF THE HYPOTHESES Table 6 and Figure 2 through Figure 10 summarize the survival analyses. Do Patients With a True Drug Short-term Response Pattern Relapse More Often While Receiving Placebo Substitution Than While Receiving Continued Fluoxetine Therapy? Among patients with a true drug short-term response pattern, the results of the primary weeks 12 to 26 Kaplan- Meier survival analysis were significant (Figure 2). The weeks 26 to 50 Kaplan-Meier survival analysis (Figure 3) also demonstrated a significantly higher relapse in placebo-treated patients. The results of the weeks 50 to 62 Kaplan-Meier survival analysis were not significant (Figure 4), although the power was poor because of the small sample size. Do Patients With a Placebo Response Pattern Relapse More Often While Receiving Placebo Than While Receiving Continued Fluoxetine Therapy? None of the primary or secondary Kaplan-Meier analyses demonstrated significantly greater relapse with the administration of placebo than with the administration of continued fluoxetine therapy (Figures 5 through 7). However, the sample size was adequate to detect a ratio of relapse with the administration of continued fluoxetine therapy vs placebo of 2.7 in the weeks 12 to 26 analysis and 3.7 in the weeks 26 to 50 analysis. That is, the weeks 12 to 26 analysis had an 80% chance of finding relapse rates of 20% vs 54% to be statistically significant. The weeks 26 to 50 analysis would have required the rates to be at least as different as 20% and 74% to have Table 1. Characteristics of 392 Randomized Patients With Short-term Response Patterns Characteristics No. (%) of Patients Age, y* 40±10 Female sex 269 (69) White 368 (94) Chronic illness 190 (48) With melancholia 95 (24) With seasonal depression 18 (5) With a bipolar history 32 (8) With recurrent depression 217 (64) With reverse neurovegetative symptoms 160 (41) No. of prior episodes* 4±8 Age at onset, y* 24±12 With a true drug response 254 (65) Baseline mhamd score* 21±4 Week 12 mhamd score* 3±2 *Data are given as the mean (±SD). N=337. mhamd indicates the modified Hamilton Depression Rating Scale. Table 2. Distribution of Pattern Types Among Randomization Groups* Randomization Group Placebo Pattern had an 80% chance of a statistically significant finding. In addition, the high dropout rate in the placebo group available for the weeks 26 to 50 analysis invalidated the use of the Kaplan-Meier analysis. While Receiving Continued Fluoxetine Therapy, Is There More Relapse in Patients With Placebo Response Patterns Than in Those With a True Drug Response Pattern? The primary (weeks 12-26) analysis demonstrated significantly less relapse with the continued administration of fluoxetine therapy in patients with a true drug response pattern compared with those with a placebo response pattern (Figure 8). The Kaplan-Meier survival analyses for weeks 26 to 50 and 50 to 62 were not significant at P=.05 (Figures 9 and 10). COMMENT True Drug Pattern Immediate placebo (n=95) 32 (34) 63 (66) Fluoxetine hydrochloride Weeks (n=96) 29 (30) 67 (70) Weeks (n=99) 36 (36) 63 (64) Weeks (n=102) 41 (40) 61 (60) *All data are given as the number (percentage) of patients in each group. 2 =2.32, df=3, P.51. Pattern analysis differentiates true drug response from placebo response during 6- to 12-week initial treatment trials The results of this study demonstrate the predictive validity of pattern analysis for the continuation (the period from the end of short-term treatment until 6 months) and maintenance (beyond 6 months) phases of 337
5 Table 3. Adequacy of Randomization* Pattern/Treatment Assignment (Group No.) No. of Patients Age, y Age at Onset, y Mean (±SD) No. of Prior Episodes Baseline mhamd Score Week 12 mhamd Score Week Placebo /placebo (1) 32 42±11 27±15 2±4 22±4 3±2 Placebo/fluoxetine hydrochloride (2) ±10 24±13 3±10 21±3 3±2 True drug /placebo (3) 63 39±10 24±12 5±7 21±3 3±2 True drug/fluoxetine (4) ±11 23±11 4±8 21±4 3±2 Hypothesis 1 (group 3 vs 4)... t=7, df=252, P.64 t=5, df=250, P.73 t=7, df=223, P.58 t=1.50, df=252, P.14 t=3, df=252, P.82 2 (group 1 vs 2)... t=1.39, df=136, P.17 t=4, df=134, P.30 t=3, df=116, P.60 t=1.22, df=44, P.23 t=8, df=136, P.39 3 (group 2 vs 4)... t=0.08, df=295, P.94 t=5, df=180, P.52 t=4, df=254, P.59 t=2, df=294, P.75 t=0, df=295, P.62 Week Placebo/placebo (1) 11 41±9 18±10 13±25 20±4 4±3 Placebo/fluoxetine (2) 37 37±10 25±14 3±5 21±3 4±3 True drug/placebo (3) 41 39±11 22±11 5±10 21±3 4±4 True drug/fluoxetine (4) 69 41±11 25±11 4±8 20±3 3±3 Hypothesis 1 (group 3 vs 4)... t=9, df=108, P.43 t=1.71, df=107, P.09 t=8, df=97, P.64 t=7, df=108, P.34 t=0, df=65, P.33 2 (group 1 vs 2)... t=1.17, df=46, P.25 t=1.58, df=46, P.13 t=1.36, df=9, P.21 t=5, df=46, P.41 t=6, df=45, P.73 3 (group 2 vs 4)... t=1.73, df=104, P.09 t=0.07, df=58, P.95 t=9, df=91, P.38 t=3, df=104, P.54 t=2.46, df=100, P.02 Week Placebo/placebo (1) 8 39±11 27±16 5±7 21±3 3±4 Placebo/fluoxetine (2) 9 36±12 27±12 4±6 22±3 4±5 True drug/placebo (3) 26 42±10 23±9 5±10 20±3 3±3 True drug/fluoxetine (4) 19 42±12 25±12 6±9 20±3 3±3 Hypothesis 1 (group 3 vs 4)... t=0.05, df=43, P.97 t=3, df=36, P.60 t=1, df=37, P.84 t=7, df=43, P.80 t=0.10, df=41, P.92 2 (group 1 vs 2)... t=6, df=15, P.66 t=0.06, df=15, P.96 t=0.12, df=14, P.91 t=7, df=15, P.46 t=9, df=15, P.70 3 (group 2 vs 4)... t=1, df=26, P.24 t=9, df=25, P.71 t=5, df=22, P.66 t=1.56, df=26, P.14 t=1, df=11, P.44 *mhamd indicates modified Hamilton Depression Rating Scale; SAD, seasonal affective disorder; NA, data are not available; and ellipses, data are not applicable. Hypothesis 1 indicates that in patients with a true drug short-term response pattern, relapse will occur more often in those treated with placebo than in those maintained on fluoxetine therapy; hypothesis 2, in patients with a placebo short-term response pattern, there will be no difference in relapse between those switched to placebo and those maintained on fluoxetine therapy; and hypothesis 3, in patients maintained on fluoxetine therapy, those with a placebo short-term response pattern will relapse more often than those with a true drug short-term response pattern. N=27. N=86. N=54. N=170. #N=10. **N=32. N=37. N=61. N=8. N=23. N=16. treatment. Hypotheses were largely confirmed because the continued administration of medication was demonstrated to be effective in patients with a true drug shortterm treatment response pattern and not in patients with other short-term response patterns. Patients with a placebo short-term response pattern had a similar prognosis whether they continued to receive fluoxetine therapy or not, although the sample size allowed at best modest power to detect differences. In contrast, following the primary switch point and 1 of the 2 secondary switch points, patients who had a true drug short-term response were significantly more likely to relapse while receiving placebo than while continuing to receive fluoxetine (P.001, P.005, and P.41, respectively). After the primary 12- week switch point, fluoxetine less effectively prevented relapse in patients who had a placebo short-term response than in those with a true drug short-term response (P.01). Thus, all 3 primary analyses, as well as 338
6 Who Are Women Who Are White With Recurrent Episodes With Melancholia No. (%) of Patients With SAD With a Chronic Illness With Bipolar Disease With Reverse Symptoms Analyses 30 (94) 29 (91) 17 (63) 7 (22) 2 (6) 15 (47) 4 (13) 14 (44) 78 (74) 101 (95) 48 (56) 21 (20) 2 (2) 60 (57) 4 (4) 47 (44) 45 (71) 55 (87) 40 (74) 19 (30) 5 (8) 28 (44) 8 (13) 25 (40) 116 (61) 183 (96) 112 (66) 48 (25) 9 (5) 87 (46) 16 (8) 74 (39) 2 =1.90, df=1, P.13 2 =4.75, df=1, P.03 2 =4.42, df=1, P.04 2 =4.46, df=1, P.04 2 =1, df=1, P.58 2 =1, df=1, P.34 2 =0.19, df=1, P.67 2 =2.06, df=1, P.16 2 =8, df=1, P.54 2 =0, df=1, P.37 2 =3, df=1, P.52 2 =7, df=1, P.49 2 =4, df=1, P.37 2 =9, df=1, P.45 2 =2.90, df=1, P.09 2 =9, df=1, P.44 2 =2.02, df=1, P.16 2 =1.63, df=1, P.21 2 =7, df=1, P.42 Analyses 6 (55) 11 (100) 7 (70)# 2 (18) 1 (9) 6 (55) 1 (9) 7 (64) 22 (60) 34 (92) 16 (50)** 7 (19) 1 (3) 18 (49) 2 (5) 12 (32) 22 (54) 41 (100) 24 (65) 15 (37) 3 (7) 21 (51) 5 (12) 18 (44) 45 (65) 67 (97) 41 (67) 15 (22) 4 (6) 27 (39) 7 (10) 25 (36) 2 =0, df=1, P.32 2 =0.14, df=1, P.71 2 =0.13, df=1, P.72 2 =0.07, df=1, P=.80 2 =3, df=1, P.47 2 =5, df=1, P.46 2 =1.95, df=1, P.17 2 =2.16, df=1, P.15 2 =0.01, df=1, P.93 2 =0.01, df=1, P.95 2 =0.05, df=1, P.82 2 =8, df=1, P.30 2 =5, df=1, P.46 2 =2, df=1, P.64 2 =5, df=1, P.43 2 =2.27, df=1, P.14 2 =0.03, df=1, P.86 Analyses 5 (63) 7 (88) 5 (63) 1 (13) 0 (0) 4 (50) 0 (0) 3 (38) 7 (78) 9 (100) 5 (63) 2 (22) 0 (0) 4 (44) 1 (11) 2 (22) 18 (69) 26 (100) 16 (70) 4 (15) 1 (4) 12 (46) 3 (12) 8 (31) 11 (58) 18 (95) 12 (75) 4 (21) 2 (11) 7 (37) 1 (5) 6 (32) 2 =2, df=1, P.64 2 =0.02, df=1, P.88 2 =6, df=1, P.55 2 =0.03, df=1, P.88 P.96 2 =0.03, df=1, P.88 2 =0.01, df=1, P.93 2 =0.08, df=1, P.78 NA 2 =0.05, df=1, P.83 2 =0.10, df=1, P.75 2 =0.04, df=1, P.47 2 =0.02, df=1, P.88 P.98 Table 4. Relapse Rates by Site* Weeks Site (17/85) 30 (11/37) 0 (0/12) 2 31 (18/58) 26 (6/23) 13 (1/8) 3 35 (40/113) 20 (9/44) 16 (3/19) 4 46 (27/59) 43 (9/21) 57 (4/7) 5 35 (27/77) 21 (7/33) 13 (2/16) *All data are given as the percentage of patients relapsing (number of patients relapsing/total number of patients at a site during the particular period indicated). For weeks 12 to 26, 2 =11.40, df=4, P.03; for weeks 26 to 50, 2 =4.38, df=4, P.36; and for weeks 50 to 62, 2 =11.25, df=4, P secondary analysis, confirmed that pattern analysis differentiates nonspecific benefit from improvement attributable to specific drug effects. Because studies validating pattern analysis have included tricyclic antidepressants, 18,19 monoamine oxidase inhibitors, 18,19 and selective serotonin reuptake inhibitors, 20,21 this technique may apply generally to antidepressant medications. Pattern analysis might be applicable to other treatments characterized by the delayed onset of persistent effects, such as lithium carbonate, antipsychotic medications, anticonvulsants, and electroconvulsive therapy. Protein synthesis represents a candidate mechanism for delayed action of treatments because its initiation takes days to weeks, while immediate effects on reuptake or receptors would be candidates if they initiated a cascade of other effects over time. These data suggest that patients with a placebo pattern of short-term response present the clinician with a dilemma. Regardless of whether fluoxetine therapy is continued, a seemingly high likelihood of relapse can be expected. If fluoxetine therapy was discontinued in a patient with a placebo response pattern, the recurrence of depressive symptoms would lead to the assumption that the medication had been responsible for the initial improvement. These results suggest that this conclusion 339
7 Table 5. Dropouts by Pattern and Treatment Assignment* Weeks Pattern/Treatment Assignment (Group No.) Placebo /placebo (1) 25 (8/32) 64 (7/11) 0 (0/8) Placebo/fluoxetine hydrochloride (2) 18 (19/106) 22 (8/37) 22 (2/9) True drug /placebo (3) 24 (15/63) 10 (4/41) 15 (4/26) True drug/fluoxetine (4) 18 (35/191) 19 (13/69) 16 (3/19) Hypothesis 1 (group 3 vs 4) 2 =0, df =1, P.35 2 =.1.62, df =1, P.21 2 =0, df =1, P.98 2 (group 1 vs 2) 2 =8, df =1, P.38 2 =6.97, df =1, P.01 2 =2.01, df =1, P.16 3 (group 2 vs 4) 2 =0.01, df =1, P.94 2 =0.11, df =1, P.74 2 =0.17, df =1, P.68 *Data are given as the percentage of patients who dropped out of the study (number of patients who dropped out/total number of patients in the particular group indicated). The hypotheses are defined in the second footnote of Table 3. Table 6. Days to Relapse* Weeks Pattern/Treatment Assignment (Group No.) Placebo /placebo (1) 69±7 (55-82) 154±13 ( ) 74±9 (57-92) Placebo/fluoxetine hydrochloride (2) 80±3 (74-85) 148±7 ( ) 70±9 (52-87) True drug /placebo (3) 68±5 (59-77) 131±9 ( ) 79±3 (72-86) True drug/fluoxetine (4) 83±2 (83-90) 154±5 ( ) 81±5 (71-90) Hypothesis 1 (group 3 vs 4) Log-rank test score=22.37, df =1, P.001 Log-rank test score=8.23, df =1, P.005 Log-rank test score=1, df =1, P.41 2 (group 1 vs 2) Log-rank test score=1.71, df =1, P.20 3 (group 2 vs 4) Log-rank test score=6.75, df =1, P.01 The log-rank test score was invalid because of a high dropout rate in the placebo group Log-rank test score=2.74, df =1, P.10 *Data are given as the mean (±SE) days to relapse (95% confidence interval) unless otherwise specified. The hypotheses are defined in the second footnote of Table 3. Log-rank test score=0.19, df =1, P.67 Log-rank test score=6, df =1, P.36 Patients Treated With Fluoxetine Hydrochloride (n=191) Patients Treated With Placebo (n=63) Days From Week 12 Figure 2. Kaplan-Meier survival curves comparing survival from weeks 12 to 26 among patients with a true drug short-term response pattern; the patients were treated with fluoxetine hydrochloride vs placebo (log-rank test score, 22.37; P.001). Vertical bars indicate points that individuals drop out before reaching relapse criteria. might be inaccurate, but it likely would be reached anyway. The discontinuation of an apparently effective agent is, therefore, problematic. Continuation would also be questionable. Although these results call into question the prophylactic efficacy of fluoxetine in patients with a placebo pattern of short-term response, as no treatment has demonstrated efficacy in patients whose short-term response could be considered to be nonspecific, we have no recommendations to make for the patient with a placebo pattern response. Loss of apparent benefit has clinical and heuristic implications. Some dramatically improved patients later relapse despite the continuation of treatment. Others relapse when the drug is withdrawn, then do not improve when the medication is reinstituted. Pattern analysis suggests that some relapse while continuing to receive medication represents loss of a placebo effect rather than loss of a true drug effect. In this study, for example, of patients relapsing while continuing to receive fluoxetine therapy, almost half (48%) had a nonspecific response pattern. Similarly, some failure to improve on second exposure to the same medication might be due to loss of a placebo effect, rather than acclimatization to pharmacological effects. Attempts to understand the treatment 340
8 Patients Treated With Fluoxetine Hydrochloride (n=69) Patients Treated With Placebo (n=41) Patients Treated With Fluoxetine Hydrochloride (n=106) Patients Treated With Placebo (n=32) Days From Week 26 Figure 3. Kaplan-Meier survival curves comparing survival from weeks 26 to 50 among patients with a true drug short-term response pattern; the patients were treated with fluoxetine hydrochloride vs placebo (log-rank test score, 8.23; df=1; P.005). Vertical bars indicate points that individuals drop out before reaching relapse criteria Days From Week 12 Figure 5. Kaplan-Meier survival curves comparing survival from weeks 12 to 26 among patients with a placebo short-term response pattern; the patients were treated with fluoxetine hydrochloride vs placebo (log-rank test score, 1.71; df=1; P.20). Vertical bars indicate points that individuals drop out before reaching relapse criteria. Patients Treated With Fluoxetine Hydrochloride (n=19) Patients Treated With Placebo (n=26) Patients Treated With Fluoxetine Hydrochloride (n=37) Patients Treated With Placebo (n=11) Days From Week 50 Figure 4. Kaplan-Meier survival curves comparing survival from weeks 50 to 62 among patients with a true drug short-term response pattern; the patients were treated with fluoxetine hydrochloride vs placebo (log-rank test score, 1; df=1; P.41). Vertical bars indicate points that individuals drop out before reaching relapse criteria Days From Week 26 Figure 6. Kaplan-Meier survival curves comparing survival from weeks 26 to 50 among patients with a placebo short-term response pattern; the patients were treated with fluoxetine hydrochloride vs placebo. The Kaplan-Meier log-rank test was invalidated by an excess of dropouts in the placebo-treated group. Vertical bars indicate points that individuals drop out before reaching relapse criteria. course of individual patients must consider the possibility that initial response was not due to direct medication effects. Unequal assignment among randomization groups could produce spurious results. For example, if men and women relapsed at different rates and were differently distributed among groups, ignoring sex effects in the analyses could yield results that seem to implicate other factors. Indeed, patterns and relapse were differentially distributed among treatment sites. However, the Cox proportional hazards analysis did not reveal significant siteby-pattern-by-treatment interaction effects on time to relapse (P.29 for weeks 12-26, P.95 for weeks 26-50, and for weeks 50-62). Other demographic and illness variables were not differentially distributed among response type, site, or comparison groups. Carryover and withdrawal effects are a concern in any discontinuation trial. Fluoxetine is not associated with withdrawal symptoms. However, the relatively long half-life of fluoxetine and its active metabolite, norfluoxetine, might delay relapse in patients switched to placebo. The resulting underestimate of relapse in placebo-treated patients 341
9 Patients Treated With Fluoxetine Hydrochloride (n=9) Patients Treated With Placebo (n=8) Patients With a True Drug Short-term Response Pattern (n=69) Patients With a Placebo Short-term Response Pattern (n=37) Days From Week 50 Figure 7. Kaplan-Meier survival curves comparing survival from weeks 50 to 62 among patients with a placebo short-term response pattern; the patients were treated with fluoxetine hydrochloride vs placebo (log-rank test score, 0.19; df=1; P.67). Vertical bars indicate points that individuals drop out before reaching relapse criteria Days From Week 26 Figure 9. Kaplan-Meier survival curves of patients treated with fluoxetine hydrochloride from weeks 26 to 50 comparing survival of those with a true drug vs a placebo short-term response pattern (log-rank test score, 2.74; df=1; P.10). Vertical bars indicate points that individuals drop out before reaching relapse criteria. Patients With a True Drug Short-term Response Pattern (n=191) Patients With a Placebo Short-term Response Pattern (n=106) Patients With a True Drug Short-term Response Pattern (n=19) Patients With a Placebo Short-term Response Pattern (n=9) Days From Week 12 Figure 8. Kaplan-Meier survival curves of patients treated with fluoxetine hydrochloride from weeks 12 to 26 comparing survival of those with a true drug vs a placebo short-term response pattern (log-rank test score, 6.75; df=1; P.01). Vertical bars indicate points that individuals drop out before reaching relapse criteria Days From Week 50 Figure 10. Kaplan-Meier survival curves of patients treated with fluoxetine hydrochloride from weeks 50 to 62 comparing survival of those with a true drug vs a placebo short-term response pattern (log-rank test score, 6; df=1; P.36). Vertical bars indicate points that individuals drop out before reaching relapse criteria. could result in failure to show between-group differences. This is one reason for caution in accepting failure to demonstrate differences in addressing hypothesis 2. An additional problem with hypothesis 2 is that in predicting no difference, it asserts the null hypothesis. What can be demonstrated is that if a difference exists it is probably smaller than x. If xis small enough, it might be judged inconsequential. The patients with placebo response patterns in this study had an 80% chance of demonstrating between-treatment differences in the weeks 12 to 26 analysis on the order of 20% vs 54%. A relapse difference of 25% vs 50% might have been missed. The detectable differences in the weeks 26 to 50 and 50 to 62 analyses were even larger. Hypothesis 2 might best be considered not disconfirmed. These results must be replicated before they should influence clinical practice. While validated for shortterm treatment with 3 classes of antidepressant medications, to our knowledge, this study is the first assessing its use beyond short-term treatment. The predictive validity of pattern analysis must be replicated for fluoxetine and extended to other selective serotonin reuptake inhibitor and non selective serotonin reuptake inhibitor antidepressant medications. 342
10 In summary, after the 3- and 6-month switch points, pattern analysis prospectively identified one patient group that showed continued medication effects (ie, different relapse rates while receiving drug vs placebo) and another group that did not. Patients who were more likely to relapse while continuing to receive fluoxetine therapy were also identified. These and previous results suggest that delayed-persistent short-term responses may identify with 80% likelihood patients who had a true drug response, while early or nonpersistent initial responses select patients with a high proportion of nonspecific improvement. In attempting to identify the mechanism of action of antidepressants, limiting inquiries to mechanisms that are delayed and persistent and testing candidate mechanisms only in patients identified as having a true drug response will likely maximize the chances of demonstrating these mechanisms. Accepted for publication July 30, This study was supported by the Eli Lilly Corp, Indianapolis, Ind. Reprints: Jonathan W. Stewart, MD, 1051 Riverside Dr, Unit 35, New York, NY REFERENCES 1. Stahl S. 5HT1A receptors and pharmacotherapy: is serotonin receptor downregulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull. 1994;30: Duncan G, Paul I, Breese G. Neuroanatomical differences on the rate of betaadrenergic receptor adaptation after repeated treatment with imipramine. Psychopharmacol Bull. 1993;29: Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry. 1991;52(suppl): Freo U, Pierini P, Dam M, Pizzolato G, Battistin I. The tricyclic antidepressant clomipramine dose dependently reduces regional cerebra metabolic rates for glucose. Psychopharmacology. 1993;113: Lucki I. Behavioral studies of serotonin receptor agonists as antidepressant drugs. J Clin Psychiatry. 1991;52(suppl): Marek C, McDougle L, Price L, Seiden I. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology. 1992;109: Hemrich-Luecke S, Snoddy H, Fuller R. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 1994;54: Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry. 1994;55(suppl A): Toth M, Shenk T. Antagonist-mediated down-regulation of 5-hydroxytryptamine type 2 receptor gene expression: modulation of transmission. Mol Pharmacol. 1994;45: Stahl S, Hanger R, Rawsch J, Fleischaber J, Hubbell-Alberts E. Down-regulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol. 1993; 16(suppl):S19-S Li Q, Levy A, Cabrera T, Brownfield M, Battaglia G, Van de Korl L. Long-term fluoxetine but not desipramine inhibits the ACTH and oxytocin responses to the 5-HT1A agonist 8-OH-DPAT in male rats. Brain Res. 1993;630: Wieland C, Fischette T, Lucki I. Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology. 1993;32: Heal D, Prow M, Gosden J, Luscombe G, Burchett W. A comparison of various antidepressant drugs demonstrates rapid desensitization of 2 -adrenoceptors exclusively by sibutramine hydrochloride. Psychopharmacology. 1992;107: Lund A, Mjellem N. Chronic combined treatment with desipramine and mianserin: enhanced 5HT1A receptor function and altered 5-HT1AV5 HT2 receptor interaction in rats. Pharmacol Biochem Behav. 1993;45: Beasley C, Masica D, Potvin J. Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology. 1992;107: Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc. 1994;69: Brown WA. Placebo as a treatment for depression. Neuropsychopharmacology. 1994;10: Quitkin F, Rabkin J, Ross D, Stewart JW. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry. 1984;41: Quitkin F, Rabkin J, Markowitz J, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry. 1987;44: Fieve R, Goodnick P, Peselow E, Barouche F, Schlegel A. Pattern analysis of antidepressant response to fluoxetine. J Clin Psychiatry. 1986;47: Dunlop S, Dornseif B, Wernicke F, Potvin J. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull. 1990; 26: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: McGlashan T, ed. The Documentation of Clinical Psychotropic Drug Trials. Rockville, Md: National Institute of Mental Health; Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, Beasley CM. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997;154:
Changes in Weight During a 1-Year Trial of Fluoxetine
Changes in Weight During a 1-Year Trial of David Michelson, M.D., Jay D. Amsterdam, M.D., Fredrick M. Quitkin, M.D., Fredrick W. Reimherr, M.D., Jerrold F. Rosenbaum, M.D., John Zajecka, M.D., Karen L.
More informationOptimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment
Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment Frederick W. Reimherr, M.D., Jay D. Amsterdam, M.D., Frederic M. Quitkin, M.D., Jerrold
More informationSuitable dose and duration of fluvoxamine administration to treat depression
PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More informationThe onset of antidepressant effects has great clinical
Article Timing of Onset of Antidepressant Response With Fluoxetine Treatment Andrew A. Nierenberg, M.D. Amy H. Farabaugh, M.A. Jonathan E. Alpert, M.D., Ph.D. Johanna Gordon, B.A. John J. Worthington,
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationA Placebo-Controlled Study of Fluoxetine Versus Imipramine in the Acute Treatment of Atypical Depression
A -Controlled Study of in the Acute Treatment of Atypical Depression Patrick J. McGrath, M.D., Jonathan W. Stewart, M.D., Malvin N. Janal, Ph.D., Eva Petkova, Ph.D., Frederic M. Quitkin, M.D., and Donald
More informationAre there differences in the responses of men and
Article Are There Differences Between Women s and Men s Antidepressant Responses? Frederic M. Quitkin, M.D. Jonathan W. Stewart, M.D. Patrick J. McGrath, M.D. Bonnie P. Taylor, M.A. Mayra S. Tisminetzky,
More informationIn order to prove the efficacy of a drug in treating major
Article Suicide Risk in -Controlled Studies Major Depression Jitschak G. Storosum, M.D. Barbara J. van Zwieten, Ph.D. Wim van den Brink, M.D., Ph.D. Berthold P.R. Gersons, M.D., Ph.D. André W. Broekmans,
More information1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.
1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationEarly response as predictor of final remission in elderly depressed patients
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry (2009) Published online in Wiley InterScience (www.interscience.wiley.com).2261 Early response as predictor of final remission in
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationSetting The setting was primary and secondary care. The economic evaluation was conducted in France.
Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Brown M C, van Loon J M, Guest J F Record Status This is a critical abstract of an
More informationORIGINAL ARTICLE. The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression
ORIGINAL ARTICLE The Effects of Adherence to Antidepressant Treatment Guidelines on Relapse and Recurrence of Depression Catherine A. Melfi, PhD; Anita J. Chawla, PhD; Thomas W. Croghan, MD; Mark P. Hanna,
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More information1. Introduction Overview Organization of Executive Summary
Executive Summary and Discussion of the Vagus Nerve Stimulation (VNS) Therapy Depression Indication Clinical Data (Updated to Include Information from Deficiency Letter Response) Prepared By: Richard L.
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationObesity among outpatients with major depressive disorder
International Journal of Neuropsychopharmacology (2005), 8, 59 63. Copyright f 2004 CINP DOI : 10.1017/S1461145704004602 Obesity among outpatients with major depressive disorder ARTICLE George I. Papakostas,
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationPatients in the MIDAS Project. Exclusion Due to Bipolarity or Psychosis. Results
Things You Think You Know Things You Think You Know, That May Not Be True in the Diagnosis and Treatment of Depression Mark Zimmerman, MD Director of Outpatient Psychiatry Director of the Partial Hospital
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationAs of this writing, more than a dozen antidepressants
Article Which Factors Influence Psychiatrists Selection of Antidepressants? Mark Zimmerman, M.D. Michael Posternak, M.D. Michael Friedman, M.D. Naureen Attiullah, M.D. Scott Baymiller, M.D. Robert Boland,
More informationMset, with some episodes clearly linked to environmental
Prevention of Relapse and Recurrence in Depression: The Role of Long-Term Pharmacotherapy and Psychotherapy Andrew A. Nierenberg, M.D.; Timothy J. Petersen, Ph.D.; and Jonathan E. Alpert, M.D. Major depressive
More informationA systematic review of the evidence on the treatment of rapid cycling bipolar disorder
Bipolar Disorders 2013: 15: 115 137 Review Article Ó 2013 John Wiley and Sons A/S Published by Blackwell Publishing Ltd. BIPOLAR DISORDERS A systematic review of the evidence on the treatment of rapid
More informationPOLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 2012 PSYCHOPHARMACOLOGY SERIES. Guna Kanniah Waikato Hospital
POLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 212 PSYCHOPHARMACOLOGY SERIES Guna Kanniah Waikato Hospital POLYPHARMACY FIVE REASONS FOR POLYPHARMACY 1. To treat a concomitant disorder 2. To treat an
More informationBackground. Population/Intervention(s)/Comparator/Outcome(s) (PICO) Duration of antipsychotic treatment in individuals with a first psychotic episode
updated 2012 Duration of antipsychotic treatment in individuals with a first psychotic episode Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationpaliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd
Re-Submission paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd 07 October 2011 The Scottish Medicines Consortium
More informationIn treatment of most chronic disorders, one of the
Regular Articles Compliance With Antidepressant Medication in the Treatment of Major Depressive Disorder in Primary Care: A Randomized Comparison of Fluoxetine and a Tricyclic Antidepressant Christopher
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationMMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION
MMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION Page 1 of 13 Table of Contents Why we need this Guideline... 3 What
More informationAre they still doing that?
Are they still doing that? Why we still give ECT and when to refer Nicol Ferrier BSc (Hons), MD, FRCP(Ed), FRCPsych Emeritus Professor of Psychiatry Newcastle University Rates of prescribing ECT in the
More informationGuidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services
Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care Illinois Department of Children and Family Services Introduction With few exceptions, children and adolescents in
More informationGraylands Hospital Drug Bulletin
Graylands Hospital Drug Bulletin Antidepressant Combination and Augmentation Strategies North Metropolitan Area Mental Health Service October 2008 Vol 15 No.4 ISSN 1323-1251 Introduction Depression is
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationRecognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD)
Objectives Recognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD) Discuss the burden of MDD on the individual and society Explore the negative impact of residual symptoms Identify
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Šagud M., Pivac N., Mustapić M., Nedić G., Mihaljević Peleš A., Kramarić M., Jakovljević M., Muck-Šeler D. (2008) The effect of lamotrigine on platelet serotonin concentration
More informationDouble-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression
Journal of Clinical Pharmacy and Therapeutics (2003) 28, 379 384 Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression S. Akhondzadeh* PhD, H.Faraji*
More informationSolving the Antidepressant Efficacy Question: Effect Sizes in Major Depressive Disorder
Clinical Therapeutics/Volume 33, Number 12, 2011 Solving the Antidepressant Efficacy Question: Effect Sizes in Major Depressive Disorder Paul A. Vöhringer, MD 1,2 ; and S. Nassir Ghaemi, MD, MPH 3 1 Facultad
More informationChapter 6 Mood Disorders and Suicide An Overview of Mood Disorders
Page 1 Extremes in Normal Mood Chapter 6 Mood Disorders and Suicide An Overview of Mood Disorders Nature of depression Nature of mania and hypomania Types of DSM-IV Depressive Disorders Major depressive
More informationSupplementary Online Content
Supplementary Online Content Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized
More informationAntidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder
updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants
More informationTOLERANCE TO ANTIDEPRESSANT TREATMENT MAY BE OVERCOME BY KETOCONAZOLE. REPORT OF TWO CASES
TOLERANCE TO ANTIDEPRESSANT TREATMENT MAY BE OVERCOME BY KETOCONAZOLE. REPORT OF TWO CASES Nicoletta Sonino* and Giovanni A. Fava** * Department of Statistical Sciences, University of Padova, Padova, Italy
More informationAntidepressant-Induced Sexual Dysfunction: A comparison between Duloxetine and Escitalopram
Original Article Antidepressant-Induced Sexual Dysfunction: A comparison between Duloxetine and Escitalopram Anurag Jhanjee*, Pankaj Kumar*, Neeraj Kumar Gupta** *Department of Psychiatry, UCMS & GTB Hospital,
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationPHARMACOLOGY Vol. I - Neuropsychopharmacology - Mirjam A.F.M. Gerrits and Jan M. van Ree
NEUROPSYCHOPHARMACOLOGY Mirjam A.F.M. Gerrits and Jan M. van Ree Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
More informationConsultant Pharmacist Approach to Major Depressive Disorder
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationConsultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO
Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationMentoring Session: Participant Cases
Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants
More informationR (paliperidone palmitate) Clinical Study Report R SCA-3004
SYNOPSIS Name of Sponsor/Company Janssen Scientific Affairs, LLC Name of Finished Product INVEGA SUSTENNA Name of Active Ingredient(s) Status: Approved Date: 10 March 2014 Prepared by: Janssen Scientific
More informationOffice Practice Coding Assistance - Overview
Office Practice Coding Assistance - Overview Three office coding assistance resources are provided in the STABLE Resource Toolkit. Depression & Bipolar Coding Reference: n Provides ICD9CM and DSM-IV-TR
More informationThe Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder
Zahedan Journal of Research in Medical Sciences Journal homepage: www.zjrms.ir The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients
More informationThe Neurobiology of Mood Disorders
The Neurobiology of Mood Disorders J. John Mann, MD Professor of Psychiatry and Radiology Columbia University Chief, Department of Neuroscience, New York State Psychiatric Institute Mood Disorders are
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationMaternal Fluoxetine Treatment in the Postpartum Period: Effects on Platelet Serotonin and Plasma Drug Levels in Breastfeeding Mother-Infant Pairs
Maternal Fluoxetine Treatment in the Postpartum Period: Effects on Platelet Serotonin and Plasma Drug Levels in Breastfeeding Mother-Infant Pairs C. Neill Epperson, MD* ; Peter I. Jatlow, MD ; Kathryn
More informationTherapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Prof. Dr. Christoph Hiemke Psychiatrische Klinik und Poliklinik Universität Mainz Psychopharmacotherapy Psychiatric Patient
More informationORIGINAL ARTICLE. Prevention of Relapse Following Cognitive Therapy vs Medications in Moderate to Severe Depression
ORIGINAL ARTICLE Prevention of Relapse Following Cognitive Therapy vs Medications in Moderate to Severe Depression Steven D. Hollon, PhD; Robert J. DeRubeis, PhD; Richard C. Shelton, MD; Jay D. Amsterdam,
More informationDepression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol
Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of
More informationClonazepam Augmentation Of Paroxetine In The Treatment Of Panic Disorder: A One Year Naturalistic Follow-Up Study
ISPUB.COM The Internet Journal of Mental Health Volume 2 Number 2 Clonazepam Augmentation Of Paroxetine In The Treatment Of Panic Disorder: A One Year Naturalistic P Dannon, I Iancu, K Lowengrub, R Amiaz,
More informationSummary of guideline for the. treatment of depression RANZCP CLINICAL PRACTICE GUIDELINES ASSESSMENT
RANZCP CLINICAL PRACTICE GUIDELINES Summary of guideline for the RANZCP CLINICAL PRACTICE GUIDELINES treatment of depression Pete M. Ellis, Ian B. Hickie and Don A. R. Smith for the RANZCP Clinical Practice
More informationDISEASES AND DISORDERS
DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related
More informationCognitive Behavioral Analysis System of Psychotherapy as a Maintenance Treatment for Chronic Depression
Journal of Consulting and Clinical Psychology Copyright 2004 by the American Psychological Association 2004, Vol. 72, No. 4, 681 688 0022-006X/04/$12.00 DOI: 10.1037/0022-006X.72.4.681 Cognitive Behavioral
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationPharmacologic Treatment of Acute Major Depression and Dysthymia
POSITION PAPERS CLINICAL GUIDELINE, PART 1 Pharmacologic Treatment of Acute Major Depression and Dysthymia Vincenza Snow, MD; Steven Lascher, DVM, MPH; and Christel Mottur-Pilson, PhD, for the American
More informationThe scope of the problem. Literature review
Past Year: Novartis Ever: Alkermes, Amylin, Behringer- Ingelheim, Biovail, Bristol-Myers Squibb, Eli Lilly, Embryon, GlaxoSmithKline, Merck, Organon, Park-Davis, Pfizer, Sanolfi-Aventis, Smith-Kline Beacham,
More informationCharles H. Kellner, MD
ECT: Learning From Recent Trials Charles H. Kellner, MD Professor, Department of Psychiatry Icahn School of Medicine at Mount Sinai ISCTM Philadelphia, PA 27 September, 2016 Charles H. Kellner, MD Disclosures
More informationTianeptine Dependence: A Case Report
CASE REPORT Tianeptine Dependence: A Case Report Syed Nabil, Ng Chong Guan, Rusdi Abd Rashid Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia Abstract
More informationClomipramine and fluoxetine effects in the treatment of panic disorder
Clomipramine and fluoxetine effects in the treatment of panic disorder Semra ^avaljuga 1, Ifeta Li~anin 2, Elvedina Kapi} 3, and Dubravka Potkonjak 3 1. Institute of Epidemiology and Biostatistics, Faculty
More informationDtients experience a chronic course, and 75% to 80% of patients
Kaymaz et al. Evidence That Patients With Single Versus Recurrent Depressive Episodes Are Differentially Sensitive to Treatment Discontinuation: A Meta-Analysis of Placebo-Controlled Randomized Trials
More informationMaintenance Phase Efficacy of Sertraline for Chronic Depression
Original Contribution Maintenance Phase Efficacy of for Chronic Depression A Randomized Controlled Trial Martin B. Keller, MD; James H. Kocsis, MD; Michael E. Thase, MD; Alan J. Gelenberg, MD; A. John
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationWhat s new in the treatment of bipolar disorder?
What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationThe relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine
International Journal of Neuropsychopharmacology (2005), 8, 523 528. Copyright f 2005 CINP doi:10.1017/s1461145705005195 The relationship between serum folate, vitamin B12, and homocysteine levels in major
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationSupplementary Online Content
Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationThe risk of experiencing depression. Patient Compliance in Depression ...PRESENTATIONS... Based on a presentation by James Jefferson, MD
...PRESENTATIONS... Patient Compliance in Depression Based on a presentation by James Jefferson, MD Presentation Summary Results of a study of comorbidity reveal that Americans have a 10.3% 1-year risk
More informationHow "Blind" Are Double-Blind Placebo-Controlled Trials of Benzodiazepine Hypnotics?
Sleep, 18(4):240-245 1995 American Sleep Disorders Association and Sleep Research Society How "Blind" Are Double-Blind Placebo-Controlled Trials of Benzodiazepine Hypnotics? Charles M. Morin, Cheryl Colecchi,
More informationDepression and the Role of L-methylfolate
Depression and the Role of L-methylfolate Depression is a chronic and recurrent disease affecting more than 18 million people in the United States, ranking it, along with heart disease, cancer and diabetes,
More informationThe Context: Why is this so important to treat?
Depression for PG1s Ian A. Cook, M.D. UCLA Department of Psychiatry Laboratory of Brain, Behavior, and Pharmacology Semel Institute for Neuroscience & Human Behavior DepressionLA.com PsychiatryGuidelines.com
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More informationPharmacological management of treatment-resistant depression
Advances in Psychiatric Treatment (1998), vol. 4, pp. 320-327 Pharmacological management of treatment-resistant depression P. J. Cowen The management of patients with depression who have failed to respond
More informationThe cientificworldjournal. Hiroaki Hori and Hiroshi Kunugi. 1. Introduction
The Scientific World Journal Volume 2012, Article ID 372474, 8 pages doi:10.1100/2012/372474 The cientificworldjournal Clinical Study The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive
More information